LUCID DIAGNOSTICS INC (LUCD)

US54948X1090 - Common Stock

0.6831  +0.01 (+1.94%)

After market: 0.69 +0.01 (+1.01%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to LUCD. LUCD was compared to 195 industry peers in the Health Care Equipment & Supplies industry. LUCD has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LUCD is valued expensive at the moment.



0

1. Profitability

1.1 Basic Checks

In the past year LUCD has reported negative net income.
In the past year LUCD has reported a negative cash flow from operations.
In the past 5 years LUCD always reported negative net income.
LUCD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -193.14%, LUCD is not doing good in the industry: 92.82% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -193.14%
ROE N/A
ROIC N/A
ROA(3y)-137.83%
ROA(5y)-244.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LUCD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

LUCD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LUCD has been increased compared to 1 year ago.
LUCD has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -13.18, we must say that LUCD is in the distress zone and has some risk of bankruptcy.
LUCD has a Altman-Z score of -13.18. This is amonst the worse of the industry: LUCD underperforms 81.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.18
ROIC/WACCN/A
WACC9.54%

2.3 Liquidity

A Current Ratio of 0.75 indicates that LUCD may have some problems paying its short term obligations.
LUCD has a worse Current ratio (0.75) than 94.87% of its industry peers.
LUCD has a Quick Ratio of 0.75. This is a bad value and indicates that LUCD is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of LUCD (0.74) is worse than 91.79% of its industry peers.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.74

4

3. Growth

3.1 Past

LUCD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.59%, which is quite good.
LUCD shows a strong growth in Revenue. In the last year, the Revenue has grown by 539.47%.
EPS 1Y (TTM)11.59%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-8.7%
Revenue 1Y (TTM)539.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q845.45%

3.2 Future

Based on estimates for the next years, LUCD will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.89% on average per year.
Based on estimates for the next years, LUCD will show a very strong growth in Revenue. The Revenue will grow by 127.64% on average per year.
EPS Next Y19.32%
EPS Next 2Y15.83%
EPS Next 3Y17.73%
EPS Next 5Y13.89%
Revenue Next Year153.66%
Revenue Next 2Y168.8%
Revenue Next 3Y165.45%
Revenue Next 5Y127.64%

3.3 Evolution

0

4. Valuation

4.1 Price/Earnings Ratio

LUCD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUCD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

LUCD's earnings are expected to grow with 17.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.83%
EPS Next 3Y17.73%

0

5. Dividend

5.1 Amount

LUCD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

LUCID DIAGNOSTICS INC

NASDAQ:LUCD (4/26/2024, 7:02:09 PM)

After market: 0.69 +0.01 (+1.01%)

0.6831

+0.01 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap32.95M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -193.14%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.75
Quick Ratio 0.74
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)11.59%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y19.32%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)539.47%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y